BI 765423 Clinical Trials (2026): 3 Studies for Healthy & Idiopathic Pulmonary Fibrosis
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
3 BI 765423 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 2 indications (including Healthy & Idiopathic Pulmonary Fibrosis) and 173 total planned enrollment. 1 BI 765423 clinical trial is actively recruiting at 6 U.S. sites across 6 states. Most recent activity: NCT07036523 (Jun 2027).
Where to Participate: All BI 765423 Trial Sites in the U.S. (6 sites across 6 states)
Every actively recruiting BI 765423trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | University of Alabama at Birmingham | Birmingham35233 | NCT07036523 | Map |
| FL | Renstar Medical Research | Ocala34470 | NCT07036523 | Map |
| MO | The Lung Research Center, LLC | Chesterfield63017 | NCT07036523 | Map |
| NY | Columbia University Medical Center-New York Presbyterian Hospital | New York10032 | NCT07036523 | Map |
| PA | Temple University Hospital | Philadelphia19140 | NCT07036523 | Map |
| TN | Clinical Trials Center of Middle Tennessee, LLC | Franklin37067 | NCT07036523 | Map |
BI 765423 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | completed | Total |
|---|---|---|---|
| P1 | 2 | 2 | |
| P2 | 1 | 1 |
Recruiting BI 765423 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07036523 | IPFA Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment | P2 | Idiopathic Pulmonary Fibrosis | 71 | Nov 2025 |
BI 765423 clinical trials by indication
Healthy (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06232252 | — | P1 | completed | A Study to Test How Well Multiple Doses of BI 765423 Are Tolerated by Healthy Men |
| NCT05658107 | — | P1 | completed | A Study to Test How Different Doses of BI 765423 Are Taken up in the Body of Healthy Men |
Idiopathic Pulmonary Fibrosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07036523 | IPF | P2 | recruiting | A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment |
BI 765423 pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| IPF | NCT07036523 | P2 | recruiting | Idiopathic Pulmonary Fibrosis | 71 | — |
All BI 765423 trials (3)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07036523 | IPF | A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment | P2 | recruiting | 71 | Boehringer Ingelheim | Nov 2025 |
| NCT06232252 | A Study to Test How Well Multiple Doses of BI 765423 Are Tolerated by Healthy Men | P1 | completed | 38 | Boehringer Ingelheim | May 2024 | |
| NCT05658107 | A Study to Test How Different Doses of BI 765423 Are Taken up in the Body of Healthy Men | P1 | completed | 64 | Boehringer Ingelheim | Jan 2023 |
BI 765423 clinical trials: frequently asked questions
- How many BI 765423 clinical trials are there?
- 3 BI 765423 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants. 2 are marked completed.
- Are BI 765423 clinical trials recruiting in 2026?
- Yes — 1 BI 765423 trial is actively recruiting in 2026, with 6 U.S. sites across 6 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is BI 765423 being studied for?
- BI 765423 is being studied for Healthy, Idiopathic Pulmonary Fibrosis. The trials are grouped by indication on this page.
- What phase is BI 765423 in?
- BI 765423 clinical trials span 1 Phase 2, 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors BI 765423 clinical trials?
- The lead sponsor across the most BI 765423 trials is Boehringer Ingelheim. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming BI 765423as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: